Professional Documents
Culture Documents
Prior to establishing his career in academic medical oncology, Mark acquired qualifications in clinical medicine (MBChB, Otago), medical oncology (FRACP) and postgraduate research (MMedSc, Auckland; PhD, London), and gained relevant experience abroad in the United Kingdom and Australia. He has published over 75 journal articles, supervised over 20 graduate students and received numerous research grants, awards and prestigious appointments relating to his work on novel anticancer drugs. He has successfully guided the development of several novel anticancer drugs through their early-phase clinical trials onto late-phase clinical development, including satraplatin (JM216) and vadimezan (ASA404, DMXAA). Mark is dedicated to reducing mortality and morbidity from cancer through patient care, education and research that transforms scientific discoveries into clinical interventions.
...
Professor Peter Browett
Peter Browett is a Consultant Haematologist at Auckland City Hospital, and Professor of Pathology and Head of the Department of Molecular Medicine and Pathology, University of Auckland.
Professor Browett is a graduate of the University of Otago School of Medicine and has worked at the Royal Free Hospital School of Medicine as a research fellow in the Academic Department of Haematology. Peter is a Fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia, and is currently Vice-President of the Haematology Society of Australia and New Zealand (HSANZ). His clinical interests include the management of patients with haematological malignancies, including blood cell and bone marrow transplantation. In the laboratory, he has an interest in cell marker and molecular studies in the diagnosis and monitoring of patients with leukaemias, lymphomas and inherited blood disorders.
Michael Findlay completed his undergraduate studies at the University of Otago. He was awarded his Fellowship of the Royal Australasian College of Physicians in 1990 after training in Wellington and Sydney. His post-Fellowship research in the treatment of gastro-intestinal cancers at the Royal Marsden Hospital in London resulted in the awarding of the degree of Doctor of Medicine in 1995. After appointments at Sydney Cancer Centre and Wellington Cancer Centre between 1994 and 2002, he was appointed as the foundation Professor in Oncology at the University of Auckland. During his appointment he established Cancer Trials New Zealand, a clinical trials coordinating centre engaged in the design and conduct of clinical and translational trials in a wide range of cancer types trials that are considered to be of particular significance to New Zealanders. Other current activities related to cancer and cancer research include: board director and deputy-chairman of the Australasian GastroIntestinal Trials Group and its Scientific Advisory Committee; member of the Genesis Oncology Trust Scientific Evaluation Committee; board member of the Auckland Division of the NewZealand Cancer Society; and member of the National Ethics Advisory Committee.
He graduated from medical school, University of Auckland in 1999 and became a Fellow of the Royal Australasian College of Physicians in 2006. Between 2006 2008 he completed a clinical research fellowship at Princess Margaret Hospital, Toronto, Canada, focusing on renal and breast malignancies before returning to New Zealand. Reuben is an active researcher in both breast and renal cancers. He is an investigator on multiple phase II and III clinical trials, including leading investigator initiated trials. He is also conducting translational research in these malignancies in collaboration with several Auckland based laboratories. The main focus of his renal cancer research is the issue of bone metastases a common site of spread in this disease associated with significant morbidity. He is currently running a phase II trial in this specific population which includes bone-specific end-points.
Experts Specialities
Overarching speciality(s) Sub-speciality(s) Type (phase) of trials
Mark McKeage Oncology - translational and clinical research Peter Browett Haematology research Mike Findlay Oncology clinical research Peter Fong Reuben Broom Oncology - translational and clinical research Oncology - translational and clinical research Head and neck cancer, clinical pharmacology and development of anticancer drugs, drug transport, platinum drugs, chemotherapy neurotoxicity, tumour vascular disruption, lung cancer Malignant haematology, bone marrow transplantation, laboratory diagnosis of haematological disorders Gastrointestinal cancers, clinical trials, expertise across most types of cancers through national collaborators Prostate, bladder, testicular, ovarian, endometrial Renal and breast cancers, bone metastases Phase I, II & III
Phase II
Contacts
Cushla Currie Business Manager - Medicine & Health +64 9 923 2585 or 021 859 188 c.currie@auckland.ac.nz Andrew Palairet Business Manager - Biomedical Sciences +64 9 923 8245 a.palairet@auckland.ac.nz Auckland UniServices Limited Level 10, UniServices House 70 Symonds Street, Auckland Private Bag 92019 AMC Auckland 1142, New Zealand www.uniservices.co.nz
SEPTEMBER 2010